Validations: CSV/CSA for Cloud/SaaS & Data Governance
Data Integrity (ALCOA+) in Cloud Workflows Data Integrity (ALCOA+) in Cloud Workflows In the rapidly evolving landscape of cloud computing within the pharmaceutical sector, ensuring data integrity has become paramount. The principles of ALCOA+—Attributable, Legible, Contemporaneous, Original, Accurate, and the additional considerations of Complete, Consistent, Enduring, and Available—serve as the foundational bedrock for maintaining high standards in data security and…
Annex 11 vs Part 11 in Cloud Context Understanding Annex 11 vs Part 11 in Cloud Context In the rapidly evolving landscape of pharmaceutical data management and validation, understanding the implications of regulatory frameworks such as Annex 11 of the EU guidelines and Part 11 of the FDA regulations is crucial. With the increasing adoption of cloud computing across the…
Understanding Annex 11 vs Part 11 in Cloud Context Introduction to Cloud Validation in the Pharmaceutical Industry The advent of cloud computing has revolutionized various industries, including pharmaceuticals. This transition raises pertinent questions about compliance, especially concerning regulations like 21 CFR Part 11 and the European Union’s Annex 11. Cloud environments, whether IaaS, PaaS, or SaaS, require validation processes to…
Supplier Audits: Paper, Remote, and On-Site Supplier Audits: Paper, Remote, and On-Site Supplier audits are critical components in the landscape of compliance within the pharmaceutical and biotechnology industries. These audits ensure that suppliers adhere to Good Manufacturing Practices (GMP), allowing for effective collaboration and risk management. As organizations increasingly leverage cloud services (IaaS, PaaS, SaaS), understanding the nuances of supplier…
Supplier Audits: Paper, Remote, and On-Site In the rapidly evolving landscape of the pharmaceutical industry, effective supplier audits are essential for ensuring compliance with various regulatory standards, notably US FDA, EMA, MHRA, and PIC/S guidelines. Auditing suppliers is not merely a best practice; it is a regulatory requirement that safeguards the integrity of pharmaceutical products through risk management and robust…
Cybersecurity Hooks: CIS/NIST and GxP Parallels Cybersecurity Hooks: CIS/NIST and GxP Parallels In the realm of pharmaceutical validation, understanding the interplay between cybersecurity standards, such as CIS (Center for Internet Security) and NIST (National Institute of Standards and Technology), and Good Automated Manufacturing Practice (GxP) requirements is essential for ensuring compliance and maintaining data integrity. This article provides a comprehensive…
Cybersecurity Hooks: CIS/NIST and GxP Parallels Cybersecurity Hooks: CIS/NIST and GxP Parallels Introduction to Cybersecurity in Pharmaceutical Validation The increasing reliance on cloud computing in the pharmaceutical industry necessitates a comprehensive understanding of the intersection between cybersecurity frameworks and Good Automated Manufacturing Practice (GxP) compliance. Recognizing the parallels between the CIS (Center for Internet Security) and NIST (National Institute of…
GxP vs Non-GxP Segregation in Multi-Tenant Tools GxP vs Non-GxP Segregation in Multi-Tenant Tools In today’s evolving pharmaceutical landscape, the use of cloud-based technologies has dramatically changed how companies approach data governance and software validation. As organizations transition to multi-tenant cloud environments, understanding the distinctions between Good Practice (GxP) and non-GxP systems becomes critical. This comprehensive guide aims to walk…
GxP vs Non-GxP Segregation in Multi-Tenant Tools GxP vs Non-GxP Segregation in Multi-Tenant Tools Introduction to GxP and Non-GxP Segregation in Multi-Tenant Tools In the rapidly evolving landscape of cloud computing, the distinction between Good Practice (GxP) and non-GxP environments within multi-tenant tools is crucial for pharmaceutical, clinical operations, and regulatory affairs professionals. This distinction ensures compliance with regulatory expectations…
Third-Party Integrations: API Risks and Evidence Third-Party Integrations: API Risks and Evidence In today’s rapidly evolving pharmaceutical landscape, the integration of third-party APIs into existing systems has become standard practice for enhancing functionalities and achieving operational efficiencies. However, these integrations also introduce distinct risks that can impact compliance with cGMP regulations and guidelines from regulatory bodies such as the US…